Phase I Study to Assess Safety of Laser-Assisted Topical Administration of an Anti-TNF Biologic in Patients With Chronic Plaque-Type Psoriasis

Publication

Phase I Study to Assess Safety of Laser-Assisted Topical Administration of an Anti-TNF Biologic in Patients With Chronic Plaque-Type Psoriasis

Journal Paper/Review - Jul 16, 2021

Bauer Martin, Brunner Patrick M, Bösch Maximilian, Braun Reinhard, Braun Werner, Böhler Christof, Ling Vincent, Pajenda Sahra, Al Jalali Valentin, Matzneller Peter, Lackner Edith, Zeitlinger Markus

Citation

Bauer M, Brunner P, Bösch M, Braun R, Braun W, Böhler C, Ling V, Pajenda S, Al Jalali V, Matzneller P, Lackner E, Zeitlinger M. Phase I Study to Assess Safety of Laser-Assisted Topical Administration of an Anti-TNF Biologic in Patients With Chronic Plaque-Type Psoriasis. Front Med (Lausanne) 2021; 8:712511.

Type

Journal Paper/Review (English)

Journal

Front Med (Lausanne) 2021; 8

Publication Date

Jul 16, 2021

Issn Print

2296-858X

Pages

712511

Brief description/objective

Ablative fractional laser treatment facilitates epidermal drug delivery, which might be an interesting option to increase the topical efficacy of biological drugs in a variety of dermatological diseases. This work aims at investigating safety and tolerability of this new treatment approach in patients with plaque-type psoriasis. Eight patients with plaque-type psoriasis were enrolled in this study. All patients received (i) ablative fractional laser microporation (AFL) of a psoriatic lesion with an Er:YAG laser + etanercept (ETA; Enbrel® solution for injection) (AFL-ETA), (ii) ETA alone on another lesion, and, if feasible, (iii) AFL alone on an additional lesion. Overall, all treatment arms showed a favorable safety profile. AFL-ETA improved the lesion-specific TPSS score by 1.75 vs. baseline, whereas ETA or AFL alone showed a TPSS score improvement of 0.75 points, a difference that was not statistically significant and might be attributable to differences in baseline scores. Topical administration of ETA to psoriatic plaques AFL-generated micropores was generally well-tolerated. No special precautions seem necessary in future studies. Clinical benefit will need assessment in sufficiently powered follow-up studies.